White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal franchise contrasting with strong growth in other areas. U.S. net sales of EYLEA ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

“Regeneron is an American success story ... invented in our New York laboratories,” President and CEO Leonard Schleifer said in a statement. “Our innovative approach has filled our ...

"Larger companies should not be allowed to use anticompetitive tactics to push competitors out of the market," Regeneron CEO Leonard Schleifer said in a statement. Tarrytown, N.Y.-based Regeneron ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...